155 related articles for article (PubMed ID: 17100108)
1. Pegylated interferon alpha-2b in patients with acute hepatitis C.
Mukhopadhyay A
Natl Med J India; 2006; 19(4):201-2. PubMed ID: 17100108
[No Abstract] [Full Text] [Related]
2. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
Malnick SD; Basevitch A
Gastroenterology; 2006 Aug; 131(2):683; author reply 683-4. PubMed ID: 16890628
[No Abstract] [Full Text] [Related]
4. Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b.
Sharara AI; Aoun E; Koussa S; Inati A; Taher A
J Gastroenterol Hepatol; 2006 Jul; 21(7):1221. PubMed ID: 16824084
[No Abstract] [Full Text] [Related]
5. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute hepatitis C-how to explain the differences?
Wedemeyer H; Cornberg M; Wiegand J; Jäckel E; Manns MP
Gastroenterology; 2006 Aug; 131(2):682-3; author reply 683-4. PubMed ID: 16890627
[No Abstract] [Full Text] [Related]
7. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
9. Interferon for hepatitis C.
Puoti C; Magrini A; Stati T; Rossi P; Montagnese F; Resta S
Lancet; 1997 Feb; 349(9049):398-9. PubMed ID: 9033470
[No Abstract] [Full Text] [Related]
10. Successful pegylated interferon alpha2a monotherapy for hepatitis C virus infection in a transplanted patient who relapsed after the preceding course.
Ichikawa T; Taura N; Miyaaki H; Matsuzaki M; Eguchi S; Takatsuki M; Kanematsu T; Nakao K
Transpl Infect Dis; 2011 Aug; 13(4):438-40. PubMed ID: 21309967
[No Abstract] [Full Text] [Related]
11. Interferon for hepatitis C patients with psychiatric disorders.
Rifai MA; Bozorg B; Rosenstein DL
Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
[No Abstract] [Full Text] [Related]
12. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients.
De Rosa FG; Mollaretti O; Audagnotto S; De Blasi T; Cariti G; Marucco DM; Bonora S; Perri GD
Clin Infect Dis; 2009 Jun; 48(11):1636-7. PubMed ID: 19416030
[No Abstract] [Full Text] [Related]
14. [Recent advances in the treatment of the acute hepatitis C].
Palumbo E
Recenti Prog Med; 2007 Apr; 98(4):236-7. PubMed ID: 17547361
[TBL] [Abstract][Full Text] [Related]
15. [Genotype 1 superresponder treat for only 24 weeks].
MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
[No Abstract] [Full Text] [Related]
16. Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-alpha 2b and ribavirin.
Buckton AJ; Kulasegaram R; Ngui SL; Fisher M; James R; Rangarajan S; Teo CG
J Clin Virol; 2007 Sep; 40(1):60-3. PubMed ID: 17631045
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
Thompson AJ; Muir AJ; Sulkowski MS; Patel K; Tillmann HL; Clark PJ; Naggie S; Fellay J; Ge D; McCarthy JJ; Goldstein DB; McHutchison JG
Hepatology; 2010 Dec; 52(6):2243-4. PubMed ID: 20890887
[No Abstract] [Full Text] [Related]
18. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
Sierra F
J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495
[No Abstract] [Full Text] [Related]
19. Clinical decisions. Management of incidental hepatitis C virus infection.
Afdhal NH; Lok AS; Di Bisceglie AM
N Engl J Med; 2009 Apr; 360(18):1902-6. PubMed ID: 19403909
[No Abstract] [Full Text] [Related]
20. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users.
Grebely J; Raffa JD; Meagher C; Duncan F; Genoway KA; Khara M; McLean M; Mead A; Viljoen M; DeVlaming S; Fraser C; Conway B
J Gastroenterol Hepatol; 2007 Sep; 22(9):1519-25. PubMed ID: 17645460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
